Allied Health & Imaging · Independent exam preparation
Certified Research Specialist Proficiency Exam Study Guide
Practise human research decisions in consent, privacy, IRB reporting, documentation and protocol design for UAMS's coursework-based CRS proficiency examination.
By CertMedbry · Updated 31 October 2026
Practise distinguishing research activities, protecting voluntary consent, assessing reportable information, correcting records and designing interpretable protocols. This guide follows the UAMS Certified Research Specialist program with the Biomedical Research–CITI coursework option. Its 60 concepts selectively support all listed course areas. The official UAMS requirements and the materials taught in those courses define the full scope; elective content depends on the approved activities completed.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which CRS examination and coursework pathway does this guide cover?
It covers the University of Arkansas for Medical Sciences Certified Research Specialist Proficiency Exam, administered through its Office of Research Integrity, using the Biomedical Research–CITI option. UAMS also accepts Social/Behavioral Research–CITI as the alternative listed CITI coursework. Those are coursework options within the UAMS program; this guide does not establish a separate examination blueprint for each option.
Certified Research Specialist Program · Certified Research Specialist Program Requirements
How many questions are on the examination, and what score is required?
UAMS states that the examination contains 20 randomly generated questions and requires 90% to pass. The public examination page does not identify a separate scored-question or pretest-question count, item weighting, or rounding policy.
What duration, delivery method and item styles are verified?
The public examination page does not specify a time limit, testing platform, proctoring arrangement, adaptive delivery or item styles. Random question generation does not establish adaptivity. UAMS directs candidates to its program contact for examination access. The four-option questions in this guide are independent learning drills, not a verified reproduction of the examination format or a pass predictor.
What is the official scope, and are domain weights available?
UAMS links examination scope to topics discussed in required program courses. The listed areas are CITI research training, Essentials, General Research Ethics, Writing SOPs, Legal Issues, Reportable New Information, Protocol Deviations, Developing a Research Protocol and electives. No domain percentages are published in the supplied official evidence. Coverage here is therefore distributed for breadth rather than presented as an official weighted blueprint.
Certified Research Specialist Program Proficiency Exam · Certified Research Specialist Program Requirements
Which curriculum version or effective date applies?
The public UAMS requirements available on October 31, 2026 provide the scope basis. The Fall 2026 schedule corroborates the named required classes. No numbered syllabus revision or examination-outline effective date is stated. Class dates are scheduling information, not blueprint effective dates. Supporting federal guidance explains research principles and does not establish additional UAMS examination requirements.
Certified Research Specialist Program Requirements · Upcoming Certified Research Specialist Courses
Who is eligible, and what coursework and fees are stated?
The registration evidence limits the program to employees of UAMS, Arkansas Children's Hospital and the VA. UAMS states that certification requires 28 coursework hours and passing the proficiency examination, and that participating in the program carries no charge. This is an institutional workforce program rather than unrestricted national registration.
Certified Research Specialist Program Registration · Certified Research Specialist Program
How do electives affect preparation?
UAMS lists research seminars, workshops and webinars as electives. Up to six external contact hours may count with approval. Individual elective content varies, so the elective examples here teach evidence appraisal and application of guidance without claiming a universal elective syllabus. Review the substantive material from your own approved activities.
How does the separate Visionary Research Association CRS differ?
Visionary Research Association Inc., in partnership with Visionary Training Center, offers a separate Certified Research Specialist credential. Its supplied issuer evidence describes 70 multiple-choice items, a three-hour maximum and a 75% passing threshold. Those details belong to that credential and do not describe the UAMS proficiency examination.
VRA Inc. — Certified Research Specialist (CRS)™ · Certified Research Specialist Program Proficiency Exam
This is independent preparation for UAMS's institutional research workforce certification, using U.S. research protections. It does not confer clinical licensure. Visionary Research Association offers a separate CRS credential with different examination arrangements.
Outline used: UAMS current public coursework-based examination scope, retrieved 2026-10-13 and corroborated by the Fall 2026 required-course schedule. No numbered syllabus revision, examination-outline effective date, or domain weights are published on the opened pages. The workbook credential label Certified Research Specialist (CRS) maps here to UAMS's Certified Research Specialist Proficiency Exam; the assigned slug is preserved. This mapping concerns the UAMS workforce certification program, not the separate Visionary Research Association credential with the same abbreviation.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Biomedical Research or Social/Behavioral Research – CITInot stated
1.What makes an activity research under the Common Rule?
Research is a systematic investigation, including development, testing and evaluation, designed to develop or contribute to generalizable knowledge. The decisive issue is the activity's design and purpose, rather than whether investigators plan publication. A structured local improvement project and a hypothesis-driven study can use similar methods but have different purposes. Research status and human-subject status are separate questions; satisfying the research definition does not by itself establish that human subjects are involved.
Apply it
A clinic compares two appointment reminders solely to improve its own scheduling. A later proposal prospectively tests a theory across clinics. Examine each activity's purpose and design separately rather than assigning both the same classification.
Common pitfall: Publication plans alone neither establish nor eliminate research status. Treating every systematic service evaluation as research overlooks the definition's generalizable-knowledge element.
2.Which individuals meet the regulatory human-subject definition?
Under the Common Rule, a human subject is a living individual about whom an investigator obtains information or biospecimens through intervention or interaction and uses, studies or analyzes them, or obtains, uses, studies, analyzes or generates identifiable private information or identifiable biospecimens. The living-individual requirement matters when reviewing records or specimens. Absence of human subjects under this definition does not eliminate separate privacy, institutional or other legal obligations.
Apply it
Investigators propose separate analyses of records from deceased patients and interviews with living relatives. Evaluate the records and interviews independently, including whose information is being studied and whether the living relatives become subjects.
Common pitfall: Do not assume every medical-record project involves Common Rule human subjects. Conversely, a project involving deceased patients can still collect research information about living relatives.
OHRP Lesson 2: What is Human Subjects Research? · HIPAA and Research
3.How do intervention and interaction differ?
Intervention includes physical procedures that gather information or biospecimens and manipulations of a subject or the subject's environment performed for research purposes. Interaction includes communication or interpersonal contact between investigator and subject. Neither term requires a drug or invasive procedure. Changing room conditions to study behavior can be an intervention, while interviewing participants is interaction. Identify what researchers do, then determine whether they use information about the living individuals involved.
Apply it
A team changes lighting in a laboratory and asks volunteers to rate concentration. The lighting manipulation is an intervention, and the questions are interaction; both contribute to the human-subject assessment of this activity.
Common pitfall: Calling a study observational does not settle classification when investigators manipulate the environment. A harmless manipulation can still be an intervention under the definition.
4.When is information private and identifiable?
Private information includes behavior occurring where a person reasonably expects no observation or recording, and information provided for specific purposes that the person reasonably expects will not be public. Identifiability concerns whether identity is or may readily be ascertained by the investigator or associated with the information. A code does not automatically remove identifiability. Consider access to the linking key and practical ability to connect records with individuals, rather than checking only for names.
Apply it
A researcher receives coded counseling records and can obtain the linking key from a collaborator. The coding arrangement does not by itself establish that the researcher cannot readily ascertain identities from the information.
Common pitfall: Replacing names with study numbers is not equivalent to eliminating identifiability. Privacy expectations also depend on the circumstances in which information was provided.
OHRP Lesson 2: What is Human Subjects Research? · OHRP: 45 CFR 46
5.How does exemption differ from absence of human-subject research?
An activity outside the human-subject research definition and research qualifying for an exemption reach different regulatory conclusions. Exempt research still meets the research and human-subject definitions but falls within a specified exemption category and its conditions. Some categories require limited IRB review. Assess the actual activities, information and population against the relevant criteria. Low perceived risk alone does not establish an exemption, and institutional procedures determine who may issue the determination.
Apply it
A team proposes identifiable adult interviews about routine workplace experiences. Rather than declaring the project outside oversight because interviews seem harmless, it examines the applicable exemption category, disclosure risks and institutional determination process.
Common pitfall: Exempt does not mean risk-free or automatically outside institutional responsibilities. Avoid substituting an investigator's informal low-risk judgment for the applicable exemption criteria.
6.Which populations receive protections under Subpart B?
HHS Subpart B addresses pregnant women, human fetuses and neonates involved in research. Its neonatal provisions distinguish neonates of uncertain viability, nonviable neonates and viable neonates, with different conditions and applicable protections. The relevant category changes the review rather than merely adding a pregnancy label. For research involving pregnancy or birth, identify exactly who is involved, the prospect of benefit and the applicable conditions before assuming ordinary adult consent is sufficient.
Apply it
A proposed neonatal study includes infants whose viability has not been determined. The team identifies the uncertain-viability provisions specifically instead of treating every infant as governed only by the ordinary adult research framework.
Common pitfall: Subpart B is not limited to pregnancy and fetuses. Omitting neonates of uncertain viability or nonviable neonates misses expressly addressed research populations.
7.Why does prisoner research require additional review?
Confinement can affect voluntariness, access to alternatives and perceptions of advantage from participation. HHS Subpart C therefore adds protections for covered research involving prisoners, including review requirements and restrictions on permissible research categories. The key assessment extends beyond whether a consent form is signed. Review the research category, selection practices and the possibility that benefits or conditions of confinement could distort a person's ability to weigh participation freely.
Apply it
A correctional facility offers a study with access to an otherwise scarce service. Reviewers examine whether that advantage compromises voluntary choice and whether the project fits a permissible prisoner-research category before considering approval.
Common pitfall: A signed consent form does not resolve the pressures created by confinement. Ordinary adult review alone may omit applicable Subpart C requirements and safeguards.
8.How do assent and parental permission protect children?
For covered research involving children, Subpart D links allowable research to risk and prospect of benefit and generally requires appropriate parental or guardian permission and child assent unless an applicable exception or waiver is justified. Assent is affirmative agreement, not mere failure to object. Whether children can assent depends on age, maturity and psychological state. A parent's permission and a child's assent serve different protective functions and should not be treated as interchangeable signatures.
Apply it
A capable adolescent declines an optional interview after a parent grants permission. The team recognizes the refusal as relevant to assent and does not treat the parent's signature as automatically authorizing participation despite that refusal.
Common pitfall: Silence is not affirmative assent. Also, adult survey exemptions cannot simply be carried over to interviews with children without examining the applicable restrictions.
Essentials of Quality Human Subject Researchnot stated
9.Why must ethical review be independent of the research team?
Independent IRB review introduces perspectives beyond investigators' scientific and operational interests. An IRB evaluates protections using scientific, nonscientific and community perspectives, with safeguards against conflicted participation. Investigator expertise remains valuable, but it cannot replace independent approval. The discriminating issue is whether review can assess participant interests without being controlled by those conducting the study. Funding, publication pressure or confidence in a respected investigator does not substitute for the required review process.
Apply it
A principal investigator offers to approve her own team's recruitment changes because she understands the science best. The institution instead routes the change through independent review and manages any reviewer conflicts affecting the decision.
Common pitfall: Scientific expertise and ethical independence answer different needs. A department's endorsement does not automatically provide the independent review required for covered human-subject research.
10.How should a study minimize research risks?
Risk minimization begins with sound design and removal of unnecessary exposure. When appropriate, investigators use procedures already performed for diagnostic or treatment purposes rather than adding avoidable procedures solely for research. Reviewers consider physical, psychological, social and informational harms, not just invasive procedures. The first decision is whether the question can be answered with less risk while retaining scientific value. Consent communicates remaining risks; it does not excuse avoidable ones.
Apply it
A study needs a laboratory value already measured during routine care. Investigators assess whether that existing result satisfies the endpoint before adding a separate research blood draw that provides no necessary scientific information.
Common pitfall: Disclosing an unnecessary procedure does not make it ethically justified. Risk minimization should change the design when comparable information can be obtained more safely.
OHRP Human Research Protection Foundational Training, Lesson 4 · OHRP: 45 CFR 46
11.How are research risks weighed against benefits?
IRB approval requires risks to be reasonable in relation to anticipated benefits, if any, to subjects and the importance of knowledge reasonably expected to result. Evaluate research-related risks rather than attributing all risks of ordinary care to the study. Distinguish direct benefit from reimbursement or general societal value. A study without direct benefit can be ethical, but its risks and expected knowledge must still justify the design under applicable population-specific rules.
Apply it
A questionnaire study offers no therapeutic benefit but addresses an important question. Reviewers consider its disclosure and distress risks against expected knowledge, rather than rejecting it solely because participants cannot receive direct medical benefit.
Common pitfall: Payment is not a substitute for anticipated health benefit in risk-benefit analysis. High compensation cannot make an otherwise unreasonable research risk acceptable to reviewers.
OHRP Human Research Protection Foundational Training, Lesson 4 · OHRP: 45 CFR 46
12.When can expedited IRB review be appropriate?
Expedited review is a regulatory review procedure, not simply a promise of faster service. For the usual initial-review route, the research must present no more than minimal risk and fit an authorized expedited-review category. Other specified uses include certain minor changes to approved research. Minimal risk concerns the probability and magnitude of harm compared with ordinary daily life or routine examinations. Neither a small sample nor an urgent recruitment deadline independently establishes eligibility.
Apply it
A small study proposes a procedure outside the relevant expedited categories. Although the investigator considers its risks low, the reviewer checks both risk level and category eligibility before choosing the appropriate review route.
Common pitfall: Minimal risk alone does not establish initial expedited-review eligibility. The term describes a permitted procedure and does not lower the substantive criteria for approval.
OHRP Human Research Protection Foundational Training, Lesson 4
13.How do privacy and confidentiality require different safeguards?
Privacy concerns access to people and their personal circumstances; confidentiality concerns how entrusted information is handled and disclosed. A private interview location protects the interaction, while access controls and secure storage protect resulting records. The same study may need both. Identify when information is collected, who can observe participation and who can later access data. Strong encryption cannot compensate for recruitment or interviews that publicly reveal a person's sensitive circumstances.
Apply it
A study interviews patients about substance use in an open waiting area, then stores recordings securely. The team moves interviews to a private space because secure storage does not address exposure during data collection.
Common pitfall: Do not equate confidentiality with the whole of privacy protection. A study can secure its database while unnecessarily exposing participation or sensitive conversations to others.
OHRP: 45 CFR 46 · OHRP Human Research Protection Foundational Training, Lesson 4
14.How should an incorrect paper research entry be corrected?
A paper correction should preserve the original entry, show the correct information and identify who made the correction and when. A single line through an error generally preserves legibility; initials, date and an explanation when needed make the change traceable. The purpose is to retain an understandable history, not produce a visually perfect record. Erasure, correction fluid and replacement pages can conceal what was originally recorded and weaken confidence in the record.
Apply it
A coordinator discovers that a visit date was transposed on a source worksheet. She draws one line through the incorrect date, enters the correct date and initials and dates the correction without obscuring the original.
Common pitfall: Rewriting a clean page may look professional but can erase the history of the error. A correction should explain the record rather than conceal it.
UAMS ORRA Study Documentation Guideline, Version 1, April 2024
15.Why must records distinguish contemporaneous entries from late entries?
Contemporaneous recording reduces dependence on memory and helps establish when study activities actually occurred. If documentation is delayed, the record should transparently identify the later entry and the event date, with its supporting basis. Backdating creates a false impression that documentation existed earlier. Reliability depends on accurate attribution, timing and traceability, whether the system is paper or electronic. A late entry can add useful information without pretending to be an original contemporaneous observation.
Apply it
A nurse notices that yesterday's completed telephone contact lacks a note. She records a dated late entry identifying the call's actual date and available supporting information, rather than making the entry appear to have been written yesterday.
Common pitfall: Completing a missing note does not justify backdating it. Distinguish when an event happened from when someone later documented or corrected the account.
UAMS ORRA Study Documentation Guideline, Version 1, April 2024 · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
16.How does delegation preserve investigator oversight?
Delegation assigns suitable tasks to qualified people while preserving investigator responsibility for appropriate oversight. Qualifications, training, task complexity and participant risk should guide assignment and supervision. A delegation record alone does not show that a person can competently perform a task. Investigators need a proportionate way to confirm that delegated activities follow the protocol and protect participants. Oversight should detect problems early rather than rely entirely on signatures collected at study initiation.
Apply it
A new coordinator is assigned eligibility screening. Before independent work, the investigator confirms training, reviews sample eligibility decisions and establishes escalation for uncertain cases instead of treating the delegation log as sufficient evidence of competence.
Common pitfall: Delegating a task does not transfer away oversight responsibility. Conversely, effective oversight does not require the investigator personally to perform every appropriately delegated activity.
E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
General Research Ethics (Parts I and II)not stated
17.How does respect for persons shape research decisions?
Respect for persons recognizes autonomous choice and requires protection for people with diminished autonomy. In practice, investigators provide understandable information, support deliberation and respect decisions to decline or withdraw. When decision-making ability is limited, additional safeguards may be needed rather than automatic exclusion or automatic enrollment through another person's permission. The central question is whether the process supports this individual's meaningful choice while addressing any relevant limitation in autonomy.
Apply it
An older adult needs extra time and a quieter setting to understand a study. The team adapts the discussion and assesses understanding rather than assuming age alone removes the person's ability to decide.
Common pitfall: Respect does not mean accepting a signature without attention to understanding. It also does not justify excluding everyone who needs communication support or additional time.
18.How can investigators assess consent comprehension?
Consent is a communication process, so comprehension must be evaluated beyond whether information was delivered. Asking participants to explain the study in their own words can reveal misunderstanding about purpose, procedures, risks and voluntariness. Re-explanation should address the specific gap using accessible language, followed by another opportunity to demonstrate understanding. The objective is meaningful understanding for a decision, not memorization of every sentence or a performance that rewards repeating the investigator's preferred words.
Apply it
A prospective participant says randomization means the physician chooses the treatment best for her. The researcher explains assignment again and asks her to describe how treatment is selected before proceeding with the enrollment decision.
Common pitfall: Asking whether someone understands often produces an uninformative yes. Reading the form aloud without checking interpretation can preserve the same misunderstanding in spoken form.
19.How do coercion and undue influence differ?
Coercion involves an overt or implicit threat of harm used to obtain compliance. Undue influence involves an inappropriate reward, offer or other influence that compromises voluntary choice. Employment, education and clinical relationships can create pressures even without an explicit threat. Evaluate the actual relationship, alternatives and consequences of refusal. Payment is not automatically coercive, but recruitment and compensation arrangements should avoid exploiting dependency or making refusal appear to threaten an existing entitlement.
Apply it
A supervisor asks employees to join a study during performance reviews. The team separates recruitment from supervisory evaluation and clarifies that participation has no employment consequences, reducing pressure created by the power relationship.
Common pitfall: Not every attractive payment is coercion, and absence of a threat does not prove voluntariness. Dependency and inappropriate inducements require their own assessment.
20.Why does justice require scrutiny of participant selection?
Justice concerns fair distribution of research burdens and benefits. Selection should follow the scientific question and relevant protections rather than convenience, easy manipulation or social disadvantage. Review both who bears study burdens and who may benefit from the resulting knowledge. Fairness does not always require identical enrollment proportions, because justified scientific or safety criteria can matter. The discriminating issue is whether exclusions and recruitment choices have defensible reasons rather than exploiting access or vulnerability.
Apply it
A team recruits only low-paid institutional workers for a burdensome study because they are easy to approach. Reviewers ask whether that population is scientifically necessary and whether the selection unfairly concentrates research burdens.
Common pitfall: Convenient access is not a complete ethical justification for recruitment. Conversely, automatically excluding disadvantaged groups can also unfairly deny participation and limit relevant knowledge.
21.What distinguishes research from individualized clinical care?
Clinical care ordinarily aims to promote an individual patient's welfare, whereas research is designed to answer questions and contribute knowledge. A study can offer potential benefit while still using procedures determined by scientific design, including randomization or extra measurements. Therapeutic misconception occurs when a participant fails to appreciate that distinction. Consent should explain which decisions follow the protocol, what benefit is uncertain and which alternatives remain available outside the study.
Apply it
A participant believes every study visit and assigned intervention has been selected solely for his personal treatment needs. The investigator explains the research purpose and protocol-driven procedures before asking him to reconsider participation.
Common pitfall: Potential therapeutic benefit does not turn every research procedure into individualized care. Avoid promising that scientific assignment necessarily selects the best treatment for each participant.
22.When must new information enter the consent process?
Consent continues after enrollment. Significant new findings that may relate to willingness to continue should be communicated through the appropriate reviewed process. The relevant decision is whether new information could reasonably change a participant's choice, not merely whether the original form was valid when signed. Depending on the change, updated documents and renewed documentation may be needed. Communication should explain the new information and available choices rather than collect another signature without discussion.
Apply it
A credible safety finding changes the known risks of an ongoing intervention. The team seeks appropriate review and informs current participants about the finding and their options instead of waiting until the next recruitment cycle.
Common pitfall: A valid initial consent does not authorize withholding material later findings. Updating a form for future recruits alone may leave current participants inadequately informed.
23.How does waiver of documentation differ from waiver of consent?
A waiver of consent documentation removes the requirement for signed consent; it does not itself remove the consent process. One basis under 45 CFR 46.117(c)(1)(ii) requires that the research present no more than minimal risk and involve no procedures for which written consent is normally required outside research. Separately, the general waiver or alteration under 46.116(f)(3) requires five IRB findings: the research involves no more than minimal risk; it could not practicably be carried out without the requested waiver or alteration; when identifiable private information or identifiable biospecimens are used, it could not practicably be carried out without using them in identifiable form; the waiver or alteration will not adversely affect subjects' rights and welfare; and, whenever appropriate, subjects or legally authorized representatives will receive additional pertinent information after participation.
Apply it
For a minimal-risk telephone interview involving only questions that would not normally require written consent outside research, the IRB may waive signatures under 46.117(c)(1)(ii). The interviewer still provides the required consent information and obtains voluntary agreement. A request to omit that consent process instead requires the separate consent-waiver findings; conducting interviews by telephone does not establish impracticability.
Common pitfall: Do not treat the minimal-risk documentation pathway as the only signature-waiver provision: 46.117 contains other bases with different conditions. Likewise, the general consent-waiver pathway differs from the special public-benefit or service-program waiver and the screening or recruitment provision. Identify the exact requirement being waived and apply that provision's criteria.
OHRP: 45 CFR 46 · OHRP Informed Consent FAQs · Federal Register :: Request Access
24.How should safeguards address limited decision-making capacity?
Decision-making capacity concerns the ability to understand relevant information, appreciate consequences and make a choice in the particular circumstances. A diagnosis alone does not establish incapacity for every research decision. Safeguards should respond to actual limitations, applicable law and study risk. These may include supported communication, assessment, an authorized representative when appropriate and attention to the individual's preferences. Respect and beneficence require protection without assuming that all cognitive limitations justify identical treatment.
Apply it
A participant with a cognitive diagnosis clearly explains a simple interview study but struggles with a more complex intervention proposal. The team assesses capacity for each decision and applies safeguards proportionate to the actual difficulty.
Common pitfall: Capacity is not established solely by a diagnostic label or a fluent conversation. A relative's presence also does not automatically establish legal authority to consent.
Writing Standard Operating Proceduresnot stated
25.What makes an SOP instruction reproducible?
A useful standard operating procedure describes a recurring task with enough detail for appropriately trained staff to perform it consistently. Instructions identify the responsible role, sequence, necessary materials, decision points and resulting records. Observable actions are more useful than aspirations such as ensuring quality. Detail should match task complexity without burying critical decisions. A reader should be able to determine what to do, when to stop and how completion is documented.
Apply it
An SOP says to handle samples appropriately. The writer replaces that phrase with the responsible role, labeling checks, processing sequence, acceptance criteria and required record, making the procedure executable by trained staff.
Common pitfall: A policy statement expresses expectations but may not explain execution. Adding length without clarifying actions and decision points does not make an SOP reproducible.
Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007
26.Why must an SOP define scope and responsibilities?
Scope establishes when a procedure applies and what activities it excludes. Responsibilities identify who performs, reviews, approves and escalates relevant work. Together they prevent staff from applying a familiar instruction to an unsuitable task or assuming someone else owns a critical action. Responsibilities should be assigned to roles rather than relying only on a particular person's name. Clear boundaries are especially useful when multiple teams share a process or an exception requires authorized judgment.
Apply it
Two teams each assume the other reviews specimen discrepancies. The revised SOP states which role checks receipt, which resolves discrepancies and when unresolved problems move to the investigator or designated responsible reviewer.
Common pitfall: Detailed steps cannot repair an undefined owner. Naming a current employee without defining the responsible role can leave the procedure unusable after staffing changes.
Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007
27.How does version control prevent procedural errors?
Version control connects each SOP to an identifiable approved revision and effective date. Controlled distribution makes the current version available where work occurs and prevents obsolete copies from remaining in active use. Superseded versions are retained appropriately to explain historical practice rather than silently overwritten. The key distinction is availability versus authorization: a document found in a shared folder may be accessible but no longer approved for current work.
Apply it
A coordinator finds two sample-processing instructions with different time limits. She verifies the approved effective version and removes the obsolete copy from active use while preserving its historical record through document control.
Common pitfall: A newer file modification date does not prove approval or effectiveness. Deleting every older version also removes evidence needed to reconstruct past procedural requirements.
Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007
28.When is an SOP ready for implementation?
An SOP should undergo appropriate technical review and approval before becoming effective. Review checks accuracy, usability and consistency with applicable requirements; implementation also requires access and suitable staff training. Approval and training serve different purposes: one authorizes the instruction, while the other prepares people to apply it. A change affecting critical work should have a controlled transition so staff know which version governs and how ongoing activities will be handled.
Apply it
A revised procedure changes a critical verification step. The unit obtains approval, sets its effective date, makes the controlled copy available and trains affected staff before expecting them to use the new workflow independently.
Common pitfall: Emailing a draft to staff does not establish controlled implementation. Approval alone also does not demonstrate that affected personnel understand the changed procedure.
Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007
29.How should an SOP conflict with a protocol be resolved?
An SOP standardizes recurring operations, while an approved protocol specifies requirements for a particular study. A generic SOP should not silently override a study-specific requirement or applicable law. When instructions conflict, staff should identify the governing requirement, involve the responsible investigator or process owner and reconcile documents through the appropriate change process. If ambiguity affects safety or validity, resolve it before the affected activity rather than inventing an informal compromise.
Apply it
A departmental SOP permits a wider visit window than a study's approved protocol. The coordinator follows the study-specific requirement and escalates the document conflict so the SOP or study instructions can be reconciled appropriately.
Common pitfall: Choosing whichever instruction is easier creates uncontrolled variation. A local SOP cannot by itself authorize a departure from an approved study protocol or applicable requirement.
Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007 · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
30.Why should SOP review respond to actual process changes?
SOP review should determine whether instructions still match authorized practice, current equipment, relevant requirements and lessons from errors. A scheduled review date is useful, but meaningful review examines substance rather than merely renewing a signature. Changes should be evaluated, approved and communicated through document control. Staff workarounds are particularly informative because they may expose unclear instructions, an impractical process or an unauthorized departure that requires correction rather than automatic incorporation.
Apply it
Repeated staff workarounds emerge after a software change. The process owner observes the workflow, assesses the risks and revises the approved SOP where justified instead of asking staff to certify that the outdated instructions remain accurate.
Common pitfall: Repeated use does not make a workaround authorized. Conversely, repeatedly retraining staff on an obsolete process may preserve the cause of error rather than solve it.
Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007
Legal Issuesnot stated
31.How does HIPAA authorization differ from research consent?
Research consent addresses agreement to participate, while HIPAA authorization permits specified uses or disclosures of protected health information by regulated entities. The requirements overlap operationally but answer different legal questions. A combined document may be possible when applicable conditions are satisfied, yet permission to participate does not automatically establish a valid HIPAA authorization. First identify the information, the covered entity's role and the proposed use or disclosure, then determine the applicable privacy permission.
Apply it
A participant signs a study consent form that contains no HIPAA authorization provisions. Before obtaining records from a covered entity, the team determines whether a valid authorization or another permitted HIPAA research pathway supports the disclosure.
Common pitfall: IRB approval and participant consent do not automatically authorize every disclosure of protected health information. Each applicable privacy permission must fit the actual data flow.
32.When may an IRB or Privacy Board waive HIPAA authorization?
A HIPAA authorization waiver requires documented findings by an IRB or Privacy Board. The use or disclosure must involve no more than minimal privacy risk, supported by safeguards, appropriate identifier-destruction planning and assurances against improper reuse or disclosure. The research must also be impracticable without the waiver and without access to the protected health information. These are separate findings. Administrative convenience or the existence of scientific value alone does not satisfy the waiver criteria.
Apply it
A retrospective study needs identifiable historical records and cannot practicably contact the entire cohort. The application explains necessity, privacy safeguards and identifier handling rather than relying solely on the difficulty of obtaining individual signatures.
Common pitfall: A waiver is not automatic for retrospective research. Difficulty obtaining authorization must be considered alongside necessity of the information and the required privacy-risk protections.
33.What makes a limited data set different from de-identified information?
A HIPAA limited data set excludes specified direct identifiers but may retain information such as dates and certain geographic detail that would not fit the Safe Harbor de-identification approach. It remains protected health information. Research use or disclosure requires a data use agreement with prescribed restrictions and safeguards. The distinction matters when exact dates are scientifically necessary: a limited data set can support that need without being described incorrectly as fully de-identified information.
Apply it
Researchers need admission dates and city-level geography but no names or other prohibited direct identifiers. The covered entity evaluates a limited data set and data use agreement rather than labeling the requested dataset Safe Harbor de-identified.
Common pitfall: Removing names alone does not create a limited data set. A qualifying limited data set also remains PHI and is not unrestricted public-use information.
34.How should coded data be assessed under HIPAA?
Coded information is not automatically HIPAA de-identified. De-identification must satisfy an accepted HIPAA method, either expert determination or Safe Harbor with its conditions. A study number may conceal a name while other fields or a usable linkage still permit identification. HIPAA and Common Rule assessments also use different definitions, so one determination should not be copied mechanically into the other. Evaluate the dataset and permitted coding arrangement against the applicable privacy standard.
Apply it
A file replaces names with random numbers but retains detailed dates and other identifying fields. The team evaluates the full dataset under HIPAA rather than assuming that assigning study codes has completed de-identification.
Common pitfall: Pseudonymous, coded and de-identified are not interchangeable conclusions. A dataset can look anonymous to a casual reader while still retaining legally significant identifying information.
35.When does the preparatory-to-research HIPAA pathway apply?
The preparatory-to-research pathway permits certain PHI access to prepare a protocol or conduct similar preparatory work based on required representations. These include that the use is solely preparatory, the PHI is necessary and no PHI will be removed from the covered entity by the researcher during the review. This is a bounded permission, not blanket authority to begin study data collection. Distinguish feasibility assessment from retaining identifiable records for the actual research.
Apply it
An investigator reviews records within a hospital to estimate whether enough eligible patients exist for a proposed protocol. Exporting identifiable charts for later study analysis would exceed the described preparatory review and needs an appropriate separate basis.
Common pitfall: A feasibility purpose does not authorize unrestricted copying or removal of PHI. Preparatory access should not quietly become enrollment or collection for the actual study.
36.How does HIPAA address research solely on decedents?
Research solely on decedents' PHI has a distinct HIPAA pathway based on representations that the use or disclosure is solely for that research and that the information is necessary. The covered entity may request documentation of death. This differs from the Common Rule's living-individual human-subject definition. Consequently, finding that a deceased-record project lacks Common Rule human subjects does not itself establish that a covered entity may disclose the requested records without a HIPAA basis.
Apply it
A team studies records exclusively from deceased patients. It distinguishes the Common Rule classification from the covered entity's HIPAA disclosure assessment and supplies the required decedent-research representations and any requested documentation of death.
Common pitfall: Death does not automatically make health records public or remove every privacy obligation. Keep the Common Rule classification separate from the HIPAA disclosure pathway.
HIPAA and Research · OHRP Lesson 2: What is Human Subjects Research?
37.How should research access match its privacy permission?
A research privacy permission should match the actual people, information, purposes and disclosures involved. Authorization, waiver documentation and data use agreements are not interchangeable grants of unlimited access. Operational controls should implement their boundaries through suitable role-based access, approved recipients and restrictions on reuse. When a collaborator requests an additional dataset or purpose, reassess the permission before disclosure. A scientifically useful extension can still fall outside the arrangement that originally permitted access.
Apply it
A collaborator approved to analyze study outcomes asks for unrelated clinical notes for a new project. The data custodian checks the governing permission and obtains the necessary additional approval or authorization before expanding access.
Common pitfall: Being a study team member does not authorize every record or future use. Technical access to a database can exceed the permission governing the information.
Reportable New Information & the IRBnot stated
38.Which three criteria identify an unanticipated problem?
OHRP describes an unanticipated problem as an incident, experience or outcome that is unexpected in nature, severity or frequency; related or possibly related to research participation; and suggests that the research places subjects or others at greater risk of harm than previously recognized. All three elements matter. The risk can be physical, psychological, economic or social. Assess the event against the protocol, consent information, population and available evidence rather than relying only on its label.
Apply it
A newly observed reaction is absent from the expected risk profile, plausibly linked to the intervention and indicates greater risk than described. The team documents the basis for all three elements in its reporting assessment.
Common pitfall: Unexpected alone is insufficient. An unrelated event does not become an unanticipated problem merely because it is severe, alarming or absent from the consent form.
OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events
39.Why is an adverse event not automatically an unanticipated problem?
Adverse events and unanticipated problems overlap but are not identical categories. An adverse event may be expected, unrelated to research or consistent with an already recognized risk, and therefore fail the unanticipated-problem criteria. Conversely, a nonmedical incident can reveal increased research risk. Separate clinical management and other reporting obligations from the specific OHRP classification. The correct assessment explains unexpectedness, relatedness and implications for risk rather than reporting every adverse event as the same regulatory category.
Apply it
A participant experiences a well-described symptom at its anticipated severity and frequency. The team provides appropriate care and documentation while separately assessing whether any feature indicates a new or greater risk requiring unanticipated-problem reporting.
Common pitfall: Classifying an event outside the unanticipated-problem category does not mean ignoring it. Clinical care, sponsor reporting and institutional documentation may still be required.
OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events
40.How can an incident be reportable without demonstrated injury?
An unanticipated problem can expose people to greater risk even when no injury has yet occurred. Unexpected loss or disclosure of identifiable sensitive research data may create social, economic or psychological risks related to participation. The assessment therefore asks what risk the incident introduced, not only whether someone has already suffered a measurable consequence. Immediate containment and preservation of relevant facts support a meaningful review of the exposure and needed protective action.
Apply it
An unencrypted file containing identifiable sensitive responses is sent to an unauthorized recipient. No participant reports harm, but the team assesses the unexpected research-related confidentiality exposure and acts to contain and report it appropriately.
Common pitfall: Waiting for proven harm can miss a risk-based reporting trigger. A confidentiality incident may meet the criteria even when recipients have not visibly misused information.
OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events
41.How do severity, seriousness and unexpectedness differ?
Severity describes an event's intensity, such as mild, moderate or severe. Under OHRP's guidance, seriousness concerns death; an immediate threat to life; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or another medically important event that may jeopardize health and require medical or surgical intervention to prevent one of these outcomes. Life-threatening means immediate risk of death when the event occurred, rather than a hypothetical risk if it had been worse. Unexpectedness compares the event's nature, severity or frequency with the approved research information and the characteristics of the population being studied.
Apply it
An intense, brief headache that resolves without danger, significant impairment or another serious-event criterion can be severe without being serious. Conversely, acute bronchospasm requiring urgent treatment to prevent respiratory failure can be medically important and serious even when treatment prevents admission. Whether either event is unexpected requires comparison with the study's risk information and population.
Common pitfall: Hospitalization is sufficient for one seriousness criterion but is not necessary for seriousness. Successful emergency intervention can prevent a serious outcome while the event still qualifies as medically important. Seriousness alone also does not establish an unanticipated problem: assess unexpectedness, research relatedness and whether the incident indicates risk greater than previously understood.
OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
42.How should possible research relatedness be evaluated?
Relatedness assessment examines whether there is a reasonable possibility that research procedures caused or contributed to an event. Timing is informative but not sufficient by itself. Consider the intervention's known effects, alternative explanations, underlying illness and whether the pattern fits a plausible connection. For OHRP's unanticipated-problem framework, possible relatedness can satisfy that element; definitive causation is unnecessary. Document uncertainty and reasoning rather than treating uncertainty as proof that the event is unrelated.
Apply it
A new symptom follows a research procedure but could also reflect the participant's disease. The investigator reviews timing, plausible mechanisms and competing explanations, then records why a research contribution remains reasonably possible or appears unlikely.
Common pitfall: After the procedure does not necessarily mean because of it. Equally, absence of definitive proof does not eliminate a reasonable possibility of research relatedness.
OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events
43.When can external information change a study's risk assessment?
Relevant new information can arise outside the local study, including findings from other sites or credible scientific reports. Its importance depends on whether it changes understanding of the risks or conduct of the current research. Investigators should evaluate applicability to the intervention, population and procedures rather than waiting for a matching local injury. Material findings can require review of protections, consent information or the protocol through the appropriate reporting and amendment processes.
Apply it
Another site reports an unexpected risk from the same intervention in a comparable population. The local investigator assesses its relevance to ongoing participants and seeks appropriate review even though no local participant has experienced the event.
Common pitfall: A local event is not required before external evidence becomes relevant. However, unrelated findings should not be imported without examining comparability and their actual implications.
OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events · OHRP Informed Consent FAQs
44.How should teams coordinate multiple reporting obligations?
One incident may require clinical action, investigator review, IRB reporting, sponsor notification and privacy or institutional escalation. These routes serve different purposes and can have different criteria and timelines. A useful assessment identifies the event, applicable framework, recipient, required content and locally governing deadline. Completing one report does not automatically satisfy every obligation. Immediate protective action should proceed as appropriate while the team documents facts and coordinates the required notifications.
Apply it
A research confidentiality incident also affects hospital-held PHI. The team contains access, informs the investigator and coordinates IRB and institutional privacy review, rather than assuming a sponsor incident report resolves every applicable obligation.
Common pitfall: There is no single universal reporting deadline for every research incident. Do not invent one or assume that notifying one recipient substitutes for all other routes.
OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events · HIPAA and Research · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
Protocol Deviationsnot stated
45.How does a protocol deviation differ from an amendment?
A deviation is a departure from the approved protocol in actual conduct. An amendment changes the authorized plan through the applicable approval process. A planned operational improvement should therefore be assessed prospectively rather than implemented first and described later as a harmless deviation. Both concepts require attention to participant protection and scientific reliability, but they answer different questions: what happened versus what is authorized to happen next. Repeated deviations may indicate that an amendment is needed.
Apply it
Staff want to replace an inconvenient study assessment with a shorter instrument. Because this changes the planned procedure, they seek the appropriate amendment review before use instead of repeatedly recording the substitution as a deviation.
Common pitfall: Calling a planned change minor does not authorize implementation. A deviation log records departures; it is not a substitute for prospective review of protocol changes.
E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
46.When may an immediate hazard justify departure from the protocol?
Current GCP recognizes that a departure may be necessary to eliminate an immediate hazard to participants without waiting for prior approval. The exception is tied to urgency and participant protection, not convenience or anticipated efficiency. Investigators should take the necessary protective action and then document the circumstances and provide required notifications promptly through applicable processes. The rationale should explain the hazard, why waiting was unsafe and what departure was necessary to address it.
Apply it
During a study procedure, a participant develops an acute threat requiring an action outside the protocol. The investigator acts to remove the immediate hazard, then documents the reason and arranges the required notifications and follow-up.
Common pitfall: The immediate-hazard exception does not cover routine scheduling problems or preferred workflow changes. Protective action also does not remove subsequent documentation and notification responsibilities.
E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
47.What should a useful deviation record explain?
A useful deviation record identifies the affected requirement, what occurred, when it occurred, who or what was affected and how the departure was detected. It also supports assessment of participant safety, rights and data reliability, along with corrective action and relevant reporting. The record should distinguish facts from later interpretation. A statement that staff were reminded is insufficient if it omits the actual departure, impact and reason the problem occurred.
Apply it
A participant's endpoint assessment occurs outside the allowed window. The record identifies the required window, actual date, reason, impact assessment and follow-up instead of recording only a generic label such as scheduling issue.
Common pitfall: A deviation count alone cannot support meaningful review. Avoid vague descriptions that prevent later reconstruction of the event or assessment of its effect on participants and data.
UAMS ORRA Study Documentation Guideline, Version 1, April 2024 · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
48.How does root-cause analysis differ from assigning blame?
Root-cause analysis examines the conditions that made a departure possible, including workflow design, unclear instructions, workload, training and system configuration. Identifying the person involved describes an event but often fails to explain recurrence. A useful cause is specific enough to support an effective change. Distinguish an isolated knowledge gap from a process that repeatedly produces errors even among trained staff. The analysis should use evidence rather than assume carelessness is the default explanation.
Apply it
Several trained coordinators schedule visits outside the protocol window. Review shows that the calendar template automatically selects an incorrect interval. Correcting the template addresses the shared cause more directly than reprimanding each coordinator.
Common pitfall: Human error is often a starting description rather than a sufficient cause. Repeated retraining will not repair an incorrect system default or an impractical workflow.
UAMS ORRA Study Documentation Guideline, Version 1, April 2024 · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
49.How should corrective action prevent recurrence?
Correction addresses the immediate problem, while preventive process changes address its cause and reduce recurrence. An effective action plan assigns responsibility, defines the change and checks whether it worked. Actions should be proportionate to risk and supported by the cause analysis. Training can be appropriate for a knowledge gap, but it is weak when the underlying problem is a defective workflow. Effectiveness review closes the loop between implementing a change and demonstrating improvement.
Apply it
After mislabeled specimens are contained, the team redesigns label verification and assigns a reviewer to examine subsequent collections. The follow-up checks whether the new process actually reduces the same error rather than merely documenting that training occurred.
Common pitfall: Closing an action when a training email is sent measures completion, not effectiveness. The chosen change should address the demonstrated cause and have a meaningful follow-up.
UAMS ORRA Study Documentation Guideline, Version 1, April 2024 · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
50.How should deviations affecting analysis be handled?
A deviation can affect interpretability without causing direct physical harm. Missed assessments, incorrect timing or prohibited co-interventions may alter the meaning of an endpoint or create bias. Preserve the underlying data, document the departure and assess its consequences using the protocol and prespecified analysis approach. Excluding inconvenient observations after seeing results can introduce additional bias. Safety significance and analysis significance should be evaluated separately because a low-safety-risk departure may still undermine scientific reliability.
Apply it
Several outcome assessments occur late in one study group. The team retains the actual dates, documents deviations and asks how timing affects the prespecified analysis instead of silently changing dates or deleting unfavorable observations.
Common pitfall: No injury does not mean no important impact. Unplanned exclusions chosen after examining treatment results can compound the bias introduced by the original protocol departure.
E6(R3) Good Clinical Practice, Guidance for Industry, September 2025 · E9 Statistical Principles for Clinical Trials, September 1998
Developing a Research Protocolnot stated
51.How should objectives and endpoints align?
A protocol turns a research question into objectives and measurable endpoints. The primary endpoint should directly represent the principal objective and specify what is measured and when. Secondary endpoints address additional questions without obscuring the main comparison. Alignment supports coherent procedures, sample-size reasoning and analysis. If the objective concerns sustained functioning but the endpoint measures only immediate satisfaction, the study may collect accurate data that do not answer its central question.
Apply it
A study aims to improve functioning three months after an intervention but proposes only a same-day satisfaction score. The team selects a suitable functional endpoint at the relevant time and retains satisfaction as a separate secondary measure.
Common pitfall: An easily collected variable is not automatically a suitable primary endpoint. Avoid letting operational convenience replace the outcome needed to answer the principal research question.
E9 Statistical Principles for Clinical Trials, September 1998 · Protocol Templates for Clinical Trials
52.What makes an endpoint operationally precise?
An operational endpoint definition identifies the variable, measurement method, assessment time and rules for deriving the analyzed value. Clear definitions reduce inconsistent interpretation across staff and sites. Terms such as improvement or response are incomplete unless their thresholds and timing are specified. The definition should be established before outcome comparisons are examined. Precision makes implementation reproducible and prevents investigators from selecting whichever reasonable interpretation happens to produce the most favorable result.
Apply it
A protocol lists improvement as its endpoint. Before enrollment, the team specifies the instrument, direction and magnitude of change, baseline reference and assessment window so every assessor applies the same definition consistently.
Common pitfall: Naming a validated instrument does not fully define the endpoint. The score, time point and derivation rule can still differ in ways that change the result.
E9 Statistical Principles for Clinical Trials, September 1998
53.How does a schedule of activities test protocol feasibility?
A schedule of activities connects each procedure to timing, responsible staff and the study question it serves. Reviewing the schedule exposes excessive burden, conflicting visit requirements and missing operational resources. Feasibility matters scientifically because impractical schedules can produce missed assessments and selective withdrawal. A template supports organization but does not replace study-specific reasoning. NIH protocol templates are recommended tools with defined intended contexts, rather than proof that every study must use one identical format.
Apply it
A proposed visit requires several assessments that exceed the clinic's available staffing and participant time. The team revises sequencing and removes unnecessary measures before enrollment, reducing foreseeable missing data and burden during conduct.
Common pitfall: A complete-looking template can still describe an unworkable study. Do not confuse filled sections with demonstrated staffing, participant acceptability or realistic assessment timing.
Protocol Templates for Clinical Trials · E9 Statistical Principles for Clinical Trials, September 1998
54.How should eligibility criteria balance safety and relevance?
Eligibility criteria define the population to which the research question applies and protect participants from unsuitable exposure. Each inclusion or exclusion should have a defensible scientific, safety or operational rationale. Excessively narrow criteria can make recruitment impractical and reduce applicability, while vague criteria invite inconsistent decisions. Criteria should be objectively assessable before enrollment. Fair selection also requires considering whether convenience-based exclusions unnecessarily prevent groups from sharing potential benefits or contributing relevant evidence.
Apply it
A protocol excludes everyone above a particular age without a stated scientific or safety reason. The team reassesses the restriction and defines any necessary risk-related criteria directly rather than relying on an unsupported age cutoff.
Common pitfall: More exclusions do not automatically create a better or safer protocol. Unjustified restrictions can weaken relevance and fairness while making recruitment unnecessarily difficult for staff.
Protocol Templates for Clinical Trials · Read the Belmont Report
55.How do randomization and allocation concealment reduce bias?
Randomization uses a chance mechanism to assign interventions, supporting comparable groups and valid statistical inference. Allocation concealment prevents people deciding enrollment from knowing upcoming assignments, reducing selection based on the next treatment. A random sequence can still be undermined if staff can inspect it before enrolling participants. These protections operate at assignment and differ from blinding after assignment. The protocol should describe both sequence generation and how future allocations remain inaccessible.
Apply it
A statistician creates a random sequence, but recruiters can view the entire list. The team restricts future assignments so recruiters cannot delay or accelerate enrollment based on which intervention will be assigned next.
Common pitfall: A random-number generator does not by itself prevent selection bias. Concealing future allocation is different from masking participants or assessors after treatment has been assigned.
E9 Statistical Principles for Clinical Trials, September 1998
56.How does blinding protect outcome assessment?
Blinding limits knowledge of assigned interventions among participants, care providers, outcome assessors or analysts as appropriate to the design. It can reduce differences in behavior, management and assessment caused by treatment expectations. When an intervention cannot realistically be hidden from participants or providers, independent masked outcome assessment may still be feasible. Specify who is blinded and how the arrangement is maintained rather than relying on an imprecise label that conceals important differences.
Apply it
Participants know which exercise program they receive, but an independent assessor can measure outcomes without knowing assignment. The protocol preserves that assessor masking instead of abandoning every form of blinding because participant masking is impossible.
Common pitfall: Blinding is not an all-or-nothing property. Saying a study is blinded without identifying who lacks assignment knowledge leaves important sources of bias unresolved in practice.
E9 Statistical Principles for Clinical Trials, September 1998
57.Why must missing-data planning begin before enrollment?
Missing outcomes can bias comparisons when missingness relates to treatment, prognosis or the unobserved result. Prevention includes feasible visits, retention planning and collection of reasons for missing assessments. The analysis plan should anticipate missing data and examine how assumptions affect conclusions. Simply analyzing complete cases or inserting a convenient value does not automatically remove bias. The critical distinction is between a computationally available method and an assumption that is credible for the study's missingness pattern.
Apply it
Investigators expect participants with poor outcomes to be more likely to miss follow-up. They plan retention measures, record reasons for absence and specify sensitivity analyses rather than assuming that the remaining participants represent everyone randomized.
Common pitfall: A larger initial sample does not automatically correct biased missingness. No single imputation method is universally valid regardless of why outcomes are absent from the dataset.
E9 Statistical Principles for Clinical Trials, September 1998
58.How does prespecification protect analysis credibility?
Prespecification establishes key endpoints, comparisons and analysis methods before investigators can choose them in response to observed treatment results. This limits selective analysis and supports interpretation of confirmatory claims. Legitimate changes can occur, but their timing, rationale and relationship to access to results should be transparent. Exploratory analyses can generate useful hypotheses when clearly distinguished from planned tests. Credibility depends on that distinction rather than pretending every later analysis was part of the original plan.
Apply it
After seeing a favorable result at one of several time points, a team wants to call it the primary endpoint. The report preserves the original primary analysis and identifies the later finding as exploratory with its rationale.
Common pitfall: Statistical significance does not retroactively make an analysis prespecified. Selecting a favorable endpoint after examining results changes the strength of the inference that can be claimed.
E9 Statistical Principles for Clinical Trials, September 1998
Electivesnot stated
59.How should a seminar result be judged beyond its p-value?
When appraising a research seminar, examine the estimated effect, its uncertainty, the study design and relevance to the population of interest. A small p-value does not establish a large or practically important effect, eliminate bias or guarantee applicability elsewhere. Confidence intervals help communicate the range of effects compatible with the analysis assumptions. This is an illustrative elective skill; the substantive topics of approved seminars vary and are not a uniform published examination suboutline.
Apply it
A seminar reports a statistically significant but small improvement from a selected population. Before recommending operational changes, the listener examines the effect estimate, uncertainty, outcome relevance and whether the study population resembles the intended local population.
Common pitfall: Statistical significance cannot replace assessment of effect size, design and relevance. A compelling presentation does not resolve uncertainty or make results applicable to every research setting.
E9 Statistical Principles for Clinical Trials, September 1998 · Certified Research Specialist Program Requirements
60.How should workshop guidance become an authorized local practice?
Applying workshop learning requires checking the guidance's scope, authority and fit with local research activities. A recommendation may inform improvement without itself changing an approved protocol or controlled SOP. Compare the proposed practice with governing requirements, assess risks and obtain the appropriate review before implementation. FDA's final September 2025 E6(R3) guidance provides current GCP principles, but its application still depends on context. Elective learning is valuable when translated through a controlled, justified process.
Apply it
After a workshop, a coordinator proposes a new documentation workflow. The team checks its fit with the protocol and local systems, evaluates traceability and obtains appropriate approval before replacing the existing controlled procedure.
Common pitfall: Attendance at a workshop does not authorize immediate procedural changes. Equally, the publication date alone does not establish that guidance applies identically to every study.
E6(R3) Good Clinical Practice (GCP) · E6(R3) Good Clinical Practice, Guidance for Industry, September 2025 · Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official required-course list as the full scope and connect each course's own materials to the selective concepts here.
- Distinguish research status, human-subject status, exemption and review route before deciding what protections apply.
- Practise consent decisions involving comprehension, voluntary choice, ongoing findings and population-specific safeguards.
- Keep Common Rule determinations separate from HIPAA permissions, especially for coded information and decedent records.
- Apply the three unanticipated-problem criteria and distinguish protective action from reporting obligations.
- Link reliable documentation, deviation analysis and controlled SOP changes to participant protection and interpretable data.
- Connect protocol objectives to operational endpoints, bias controls, feasible follow-up and prespecified analysis.
- Review the substantive learning from your own approved electives; their content is not a uniform public topic list.
A practical preparation plan
1. Map the required coursework
Create a course-by-course map using the UAMS requirements. Place your Biomedical Research–CITI learning, class materials and approved elective notes under the matching areas, and identify content beyond this selective guide.
2. Practise classification decisions
For short scenarios, decide whether the activity is research, involves living human subjects, fits an exemption or requires a particular review route. State the decisive criterion rather than relying on a label.
3. Trace permission and information flows
Draw who collects, uses and receives study information. Identify the consent process, any HIPAA permission, access boundaries and safeguards needed at each point.
4. Work through incident assessments
For each event, separate immediate protection, unexpectedness, relatedness, increased risk, documentation and reporting routes. For deviations, add a cause analysis and a measurable recurrence-prevention action.
5. Audit a miniature protocol
Check whether its objective, endpoint, eligibility, schedule and analysis answer one coherent question. Look specifically for foreseeable missing data, exposed allocations and outcome assessors who could be masked.
6. Use the drills to repair reasoning gaps
Answer the questions before reading explanations, then explain why each alternative is less appropriate. Revisit the matching course material and use the flashcards to recall the discriminating rule without answer options.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Certified Research Specialist Program
- Certified Research Specialist Program Proficiency Exam
- Certified Research Specialist Program Requirements
- Certified Research Specialist Program Registration
- Upcoming Certified Research Specialist Courses
- VRA Inc. — Certified Research Specialist (CRS)™
- OHRP Lesson 2: What is Human Subjects Research?
- OHRP: 45 CFR 46
- OHRP Lesson 3: What are IRBs?
- OHRP Human Research Protection Foundational Training, Lesson 4
- UAMS ORRA Study Documentation Guideline, Version 1, April 2024
- Read the Belmont Report
- OHRP Informed Consent FAQs
- Guidance for Preparing Standard Operating Procedures, EPA QA/G-6, April 2007
- HIPAA and Research
- OHRP Guidance: Reviewing and Reporting Unanticipated Problems and Adverse Events
- E6(R3) Good Clinical Practice (GCP)
- E6(R3) Good Clinical Practice, Guidance for Industry, September 2025
- Protocol Templates for Clinical Trials
- E9 Statistical Principles for Clinical Trials, September 1998
- Subpart B — Additional Protections for Pregnant Women, Human Fetuses and Neonates Involved in Research
- Federal Register :: Request Access
- Federal Register :: Request Access
- Payment and Reimbursement to Research Subjects | FDA
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.